These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 34963879)

  • 1. Framework for Risk Communication and Community Engagement to Improve Vaccine Uptake for COVID-19 and other Vaccine-Preventable Diseases in Low- and Middle-Income Countries (LMIC).
    Gonah L; Kobie AG
    Ann Glob Health; 2021; 87(1):123. PubMed ID: 34963879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Al-Shaikh A; Muthu N; Aidyralieva C; Profili MC; Bellizzi S
    Vaccine; 2021 Aug; 39(34):4769-4771. PubMed ID: 34281741
    [No Abstract]   [Full Text] [Related]  

  • 3. Behavioral and social science in support of SARS-CoV-2 vaccination: National Institutes of Health initiatives.
    Hunter CM; Chou WS; Webb Hooper M
    Transl Behav Med; 2021 Jul; 11(7):1354-1358. PubMed ID: 34080616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The global burden of vaccine-preventable infectious diseases in children less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?
    Frenkel LD
    Allergy Asthma Proc; 2021 Sep; 42(5):378-385. PubMed ID: 34474707
    [No Abstract]   [Full Text] [Related]  

  • 5. Ensuring the global COVID-19 vaccine equity: Universal vaccine access strategy in the context of low and-middle-income countries.
    Parray AA; Yadav UN; Das A; Ali AM; Mollick S; Saha S; Mistry SK
    Glob Public Health; 2022 Apr; 17(4):614-621. PubMed ID: 35050840
    [No Abstract]   [Full Text] [Related]  

  • 6. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk communication and community engagement as an emerging pillar of health emergency management in Iran: Achievements and the way forward.
    Senga M; Kouhestani M; Hosseini Boroujeni SM; Ghaderi E; Parchami P; Hussain SJ
    Front Public Health; 2023; 11():1097932. PubMed ID: 36875388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes towards vaccines and intention to vaccinate against COVID-19: a cross-sectional analysis-implications for public health communications in Australia.
    Enticott J; Gill JS; Bacon SL; Lavoie KL; Epstein DS; Dawadi S; Teede HJ; Boyle J;
    BMJ Open; 2022 Jan; 12(1):e057127. PubMed ID: 34980631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of COVID-19 on vaccination programs: adverse or positive?
    Ali I
    Hum Vaccin Immunother; 2020 Nov; 16(11):2594-2600. PubMed ID: 32961081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latin American forum on immunization services during the COVID-19 pandemic.
    Ávila-Agüero ML; Ospina-Henao S; Pirez MC; Gentile Á; Araya S; Brea J; Mendoza L; Falleiros-Arlant LH
    Expert Rev Vaccines; 2021 Mar; 20(3):231-234. PubMed ID: 33554682
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 Risk Communication and Community Engagement (RCCE) in Malawi: Challenges and Response.
    Maganga CF; Ngwira FF; Gondwe G; Nyang'wa B; Kunkumbira T
    Health Promot Pract; 2024 Jul; 25(4):578-588. PubMed ID: 38153005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key Considerations for Successful Risk Communication and Community Engagement (RCCE) Programmes During COVID-19 Pandemic and Other Public Health Emergencies.
    Gonah L
    Ann Glob Health; 2020 Nov; 86(1):146. PubMed ID: 33262935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Mazur A; Benitez S; Chuffart-Finsterwald S; La Rotta R; Hampton LM
    Vaccine; 2021 Dec; 39(49):7128-7130. PubMed ID: 34732277
    [No Abstract]   [Full Text] [Related]  

  • 14. The Vaccine Communication Demands on Community-Based Workforces.
    Rauh L; Patry D; Zambrano M; Lathan HS; Tavarez E; El-Mohandes A
    Front Public Health; 2022; 10():827378. PubMed ID: 35186850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine hesitancy among people with multiple sclerosis.
    Yap SM; Al Hinai M; Gaughan M; Callanan I; Kearney H; Tubridy N; McGuigan C
    Mult Scler Relat Disord; 2021 Nov; 56():103236. PubMed ID: 34507240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Offering onsite COVID-19 vaccination to high-risk obstetrical patients: initial findings.
    Hirshberg JS; Huysman BC; Oakes MC; Cater EB; Odibo AO; Raghuraman N; Kelly JC
    Am J Obstet Gynecol MFM; 2021 Nov; 3(6):100478. PubMed ID: 34481996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk communication and community engagement strategies for COVID-19 in 13 African countries.
    Adebisi YA; Rabe A; Lucero-Prisno Iii DE
    Health Promot Perspect; 2021; 11(2):137-147. PubMed ID: 34195037
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges and solutions: surveying researchers on what type of community engagement and involvement activities are feasible in low and middle income countries during the COVID-19 pandemic.
    Kroese K; Porter K; Surridge H; Tembo D
    BMJ Open; 2021 Oct; 11(10):e052135. PubMed ID: 34706957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.
    Sharun K; Dhama K
    Arch Med Res; 2021 Oct; 52(7):761-763. PubMed ID: 33941393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfolding the Determinants of COVID-19 Vaccine Acceptance in China.
    Yin F; Wu Z; Xia X; Ji M; Wang Y; Hu Z
    J Med Internet Res; 2021 Jan; 23(1):e26089. PubMed ID: 33400682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.